Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China
$3 million milestone payment for Chinese approval of OLINVYK (oliceridine) injection The Company also eligible to receive $15 million non-dilutive financing tranche from R-Bridge upon first...
CHESTERBROOK, Pa., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that China’s National Medical Products Administration (NMPA) has accepted submission of a New Drug Application (NDA) for oliceridine injection. The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa of a Phase 3 bridging trial for OLINVYK (oliceridine) injection, a novel IV analgesic that has been approved in the United States by the Food and Drug Administration (FDA) for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.
Following years of preparation, scientists from Brigham and Women's Hospital are ready to start a clinical trial that will evaluate the use of an intranasal vaccine to prevent Alzheimer's disease (AD).
Complix has signed a global collaboration and license agreement with Jiangsu Nhwa Pharmaceutical Co, to develop Cell Penetrating Alphabodies (CPABs), able to cross the blood brain barrier, for the improved treatment of diseases of the central nervous system (CNS).
CHESTERBROOK, Pa., June 03, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine, Trevena’s lead investigational asset for the management of moderate-to-severe acute pain. Jiangsu Nhwa holds an exclusive license agreement for the development and commercialization of oliceridine in China.
Jiangsu NHWA Pharmaceutical Receives FDA Warning Letter
I-Mab Biopharma, a clinical stage biotech based in Shanghai with an exclusive focus on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases, and Jiangsu Nhwa Pharmaceutical (Nhwa), a company devoted to central nervous system (CNS) drug development, manufacturing and service, have entered into a collaborative research agreement with scientists and clinicians at the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital and Biodextris, a Montreal-based biologics contract development and manufacturing organization, to jointly develop a novel immuno-stimulatory therapy for neurologic disorders by harnessing the natural power of the immune system.